PE20091732A1 - Dihidropirazolonas sustituidas y su uso - Google Patents
Dihidropirazolonas sustituidas y su usoInfo
- Publication number
- PE20091732A1 PE20091732A1 PE2009000514A PE2009000514A PE20091732A1 PE 20091732 A1 PE20091732 A1 PE 20091732A1 PE 2009000514 A PE2009000514 A PE 2009000514A PE 2009000514 A PE2009000514 A PE 2009000514A PE 20091732 A1 PE20091732 A1 PE 20091732A1
- Authority
- PE
- Peru
- Prior art keywords
- cyclobutylpiperazin
- pyrimidin
- compounds
- dihidro
- pirazol
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Abstract
SE REFIERE A COMPUESTOS DERIVADOS DE DIHIDROPIRAZOLONA DE FORMULA (I) DONDE X ES N O CH; R1 ES H O CN; R2 ES HETEROCICLILO DE 4 A 7 MIEMBROS QUE ESTA UNIDO A TRAVES DE UN ATOMO DE N OPCIONALMENTE SUSTITUIDO CON HIDROXILO, HIDROXICARBONILO, ALQUILO(C1-C3), ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 2-[6-(4-CICLOBUTILPIPERAZIN-1-IL)PIRIMIDIN-4-IL]-4-(1H-IMIDAZOL-1-IL)-1,2-DIHIDRO-3H-PIRAZOL-3-ONA, 2-[6-(4-CICLOBUTILPIPERAZIN-1-IL)PIRIMIDIN-4-IL]-4-(1H-1,2,3-TRIAZOL-1-IL)-1,2-DIHIDRO-3H-PIRAZOL-3-ONA, 1-{2-[6-(4-CICLOBUTILPIPERAZIN-1-IL)PIRIMIDIN-4-IL]-3-OXO-2,3-DIHIDRO-1H-PIRAZOL-4-IL}-1H-IMIDAZOL-4-CARBONITRILO, ENTRE OTROS. SE REFIERE TAMBIEN A UN PROCEDIMIENTO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE HIF PROLIL-4-HIDROXILASAS SIENDO UTILES EN EL TRATAMIENTO DE INSUFICIENCIA CARDIACA, ANEMIA, ANGINA DE PECHO, INFARTO DE MIOCARDIO
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102008020113A DE102008020113A1 (de) | 2008-04-23 | 2008-04-23 | Substituierte Dihydropyrazolone und ihre Verwendung |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20091732A1 true PE20091732A1 (es) | 2009-12-05 |
Family
ID=40673347
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2009000514A PE20091732A1 (es) | 2008-04-23 | 2009-04-14 | Dihidropirazolonas sustituidas y su uso |
Country Status (30)
Country | Link |
---|---|
US (3) | US8067407B2 (es) |
EP (1) | EP2265602B1 (es) |
JP (1) | JP5579165B2 (es) |
KR (1) | KR20100135838A (es) |
CN (1) | CN102015685B (es) |
AR (1) | AR071376A1 (es) |
AU (1) | AU2009240311B2 (es) |
BR (1) | BRPI0911594A2 (es) |
CA (1) | CA2722016C (es) |
CL (1) | CL2009000906A1 (es) |
CO (1) | CO6300844A2 (es) |
CR (1) | CR11684A (es) |
DE (1) | DE102008020113A1 (es) |
DO (1) | DOP2010000282A (es) |
EC (1) | ECSP10010494A (es) |
ES (1) | ES2535458T3 (es) |
HK (1) | HK1156306A1 (es) |
HN (1) | HN2010001920A (es) |
IL (1) | IL208136A0 (es) |
MA (1) | MA32251B1 (es) |
MX (1) | MX2010010324A (es) |
NZ (1) | NZ588721A (es) |
PE (1) | PE20091732A1 (es) |
RU (1) | RU2509080C9 (es) |
SV (1) | SV2010003674A (es) |
TW (1) | TWI433846B (es) |
UA (1) | UA105487C2 (es) |
UY (1) | UY31765A (es) |
WO (1) | WO2009129945A1 (es) |
ZA (1) | ZA201006719B (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102008020113A1 (de) * | 2008-04-23 | 2009-10-29 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Dihydropyrazolone und ihre Verwendung |
DE102005019712A1 (de) | 2005-04-28 | 2006-11-09 | Bayer Healthcare Ag | Dipyridyl-dihydropyrazolone und ihre Verwendung |
DE102006050516A1 (de) * | 2006-10-26 | 2008-04-30 | Bayer Healthcare Ag | Substituierte Dihydropyrazolone und ihre Verwendung |
CN103052632B (zh) * | 2010-08-18 | 2014-03-19 | 山东亨利医药科技有限责任公司 | 二氢吡唑类化合物 |
DE102010044131A1 (de) | 2010-11-18 | 2012-05-24 | Bayer Schering Pharma Aktiengesellschaft | Substituiertes Natrium-1H-pyrazol-5-olat |
GB201102659D0 (en) | 2011-02-15 | 2011-03-30 | Isis Innovation | Assay |
WO2012126275A1 (zh) * | 2011-03-18 | 2012-09-27 | 山东亨利医药科技有限责任公司 | 含有螺环的二氢吡唑类化合物 |
GB201113101D0 (en) | 2011-07-28 | 2011-09-14 | Isis Innovation | Assay |
US9365562B2 (en) | 2011-10-06 | 2016-06-14 | Merck Sharp & Dohme Corp. | 1,3 substituted azetidine PDE10 inhibitors |
US20140329797A1 (en) * | 2011-10-17 | 2014-11-06 | Bayer Intellectual Property Gmbh | Substituted oxadiazolyl pyridinones and oxadiazolyl pyridazinones as hif inhibitors |
MX358660B (es) | 2012-01-12 | 2018-08-30 | Univ Yale | Compuestos y metodos para degradacion mejorada de proteinas y otros polipeptidos elegidos como blanco mediante una ubiquitina ligasa e3. |
TW201400470A (zh) | 2012-03-30 | 2014-01-01 | Daiichi Sankyo Co Ltd | 4-烷醇胺-3-吡唑哢衍生物 |
AP2014008089A0 (en) | 2012-05-08 | 2014-11-30 | Bayer Pharma AG | Method for the preparation of triazole compounds |
JOP20190080A1 (ar) | 2016-10-14 | 2019-04-11 | Bayer Pharma AG | مركبات مشتقة من 6-(1h-بيرازول-1-يل) بيريميدين-4- أمين مستبدل واستخداماتها |
US11180480B2 (en) * | 2017-10-17 | 2021-11-23 | Sensorion | Synthesis of 4-aminopyrimidine compounds |
CN109694380B (zh) * | 2017-10-23 | 2022-09-27 | 中国医药研究开发中心有限公司 | 二氢吡唑啉酮类化合物及其制备方法和医药用途 |
CN111825690B (zh) * | 2019-04-17 | 2022-09-27 | 中国医药研究开发中心有限公司 | 一种phd抑制剂的新晶型及其制备方法 |
CN111825689B (zh) * | 2019-04-17 | 2023-05-05 | 中国医药研究开发中心有限公司 | 一种二氢吡唑啉酮类化合物的晶型及其制备方法 |
CA3160364A1 (en) * | 2019-11-19 | 2021-05-27 | Modag Gmbh | Compounds, and their use for the diagnosis, treatment and prevention of diseases associated with the aggregation of alpha-synuclein |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4075003A (en) * | 1975-12-11 | 1978-02-21 | Eli Lilly And Company | Novel herbicidal method utilizing 1,4-diphenyl-3-pyrazolin-5-ones |
GR63123B (en) | 1975-12-11 | 1979-09-11 | Lilly Co Eli | Preparation process of novel 1,4-diphenyl-3-pyrazolin-5-ones |
PL103509B1 (pl) * | 1976-09-20 | 1979-06-30 | Lilly Co Eli | Srodek chwastobojczy |
US4663327A (en) * | 1984-05-23 | 1987-05-05 | Bayer Aktiengesellschaft | 1-heteroaryl-4-aryl-pyrazolin-5-ones |
DE3443308A1 (de) * | 1984-11-28 | 1986-05-28 | Bayer Ag, 5090 Leverkusen | 1-heteroaryl-4-aryl-pyrazolin-5-one zur verwendung als arzneimittel |
DE3527157A1 (de) | 1985-07-30 | 1987-02-12 | Bayer Ag | 1-heteroaryl-4-aryl-pyrazol-derivate |
FR2725988B1 (fr) | 1994-10-24 | 1997-01-24 | Roussel Uclaf | Nouveaux derives de pyrazolones et pyrazoles acides, leur procede de preparation, les nouveaux intermediaires obtenus, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant |
DE19909237A1 (de) | 1999-03-03 | 2000-09-07 | Merck Patent Gmbh | Pyrazol-3-on-derivate |
US6878729B2 (en) * | 2001-05-04 | 2005-04-12 | The Procter & Gamble Company | Medicinal uses of dihydropyrazoles |
CA2446864C (en) | 2001-05-16 | 2011-02-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of src and other protein kinases |
JP4286146B2 (ja) | 2001-12-18 | 2009-06-24 | メルク エンド カムパニー インコーポレーテッド | メタボトロピックグルタミン酸受容体−5のヘテロアリール置換ピラゾール系調節剤 |
AU2003213673A1 (en) | 2002-03-01 | 2003-09-16 | Pintex Pharmaceuticals, Inc. | Pin1-modulating compounds and methods of use thereof |
US8124582B2 (en) | 2002-12-06 | 2012-02-28 | Fibrogen, Inc. | Treatment of diabetes |
WO2004087066A2 (en) * | 2003-03-27 | 2004-10-14 | Emory University | Hif-1 inhibitors |
US20060194807A1 (en) | 2003-04-03 | 2006-08-31 | Cosford Nicholas D P | Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5 |
CA2525298A1 (en) * | 2003-05-01 | 2004-11-18 | Panacea Pharmaceuticals, Inc. | Methods of treating ischemic related conditions |
CN1842332A (zh) * | 2003-06-30 | 2006-10-04 | Hif生物公司 | 化合物、组合物及方法 |
WO2005030121A2 (en) | 2003-06-30 | 2005-04-07 | Hif Bio, Inc. | Compounds, compositions and methods |
WO2006088491A2 (en) * | 2004-06-29 | 2006-08-24 | Massachusetts Institute Of Technology | Methods and compositions related to the modulation of intercellular junctions |
DE102008020113A1 (de) * | 2008-04-23 | 2009-10-29 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Dihydropyrazolone und ihre Verwendung |
KR20070112276A (ko) | 2005-03-16 | 2007-11-22 | 아벤티스 파마슈티칼스 인크. | 중추신경계 약제로서의 디피라졸 |
DE102005019712A1 (de) | 2005-04-28 | 2006-11-09 | Bayer Healthcare Ag | Dipyridyl-dihydropyrazolone und ihre Verwendung |
WO2007008541A2 (en) | 2005-07-08 | 2007-01-18 | Kalypsys, Inc. | Cellular cholesterol absorption modifiers |
DE102006050516A1 (de) * | 2006-10-26 | 2008-04-30 | Bayer Healthcare Ag | Substituierte Dihydropyrazolone und ihre Verwendung |
DE102006050513A1 (de) | 2006-10-26 | 2008-04-30 | Bayer Healthcare Ag | Substitiuierte Dihydropyrazolone und ihre Verwendung |
DE102006050515A1 (de) | 2006-10-26 | 2008-04-30 | Bayer Healthcare Ag | Substituierte Dipyridiyl-dihydropyrazolone und ihre Verwendung |
JP5237712B2 (ja) * | 2008-07-25 | 2013-07-17 | 公立大学法人 滋賀県立大学 | 静電紡糸装置 |
-
2008
- 2008-04-23 DE DE102008020113A patent/DE102008020113A1/de not_active Withdrawn
-
2009
- 2009-04-11 RU RU2010147404/04A patent/RU2509080C9/ru not_active IP Right Cessation
- 2009-04-11 JP JP2011505403A patent/JP5579165B2/ja not_active Expired - Fee Related
- 2009-04-11 CA CA2722016A patent/CA2722016C/en not_active Expired - Fee Related
- 2009-04-11 UA UAA201013898A patent/UA105487C2/uk unknown
- 2009-04-11 KR KR1020107023631A patent/KR20100135838A/ko not_active Application Discontinuation
- 2009-04-11 EP EP09733899.0A patent/EP2265602B1/de active Active
- 2009-04-11 CN CN200980114292.9A patent/CN102015685B/zh not_active Expired - Fee Related
- 2009-04-11 NZ NZ588721A patent/NZ588721A/xx not_active IP Right Cessation
- 2009-04-11 BR BRPI0911594A patent/BRPI0911594A2/pt not_active IP Right Cessation
- 2009-04-11 AU AU2009240311A patent/AU2009240311B2/en not_active Ceased
- 2009-04-11 MX MX2010010324A patent/MX2010010324A/es active IP Right Grant
- 2009-04-11 ES ES09733899.0T patent/ES2535458T3/es active Active
- 2009-04-11 WO PCT/EP2009/002693 patent/WO2009129945A1/de active Application Filing
- 2009-04-14 PE PE2009000514A patent/PE20091732A1/es not_active Application Discontinuation
- 2009-04-14 UY UY0001031765A patent/UY31765A/es not_active Application Discontinuation
- 2009-04-15 CL CL2009000906A patent/CL2009000906A1/es unknown
- 2009-04-17 AR ARP090101367A patent/AR071376A1/es not_active Application Discontinuation
- 2009-04-22 US US12/427,749 patent/US8067407B2/en active Active
- 2009-04-22 TW TW098113265A patent/TWI433846B/zh not_active IP Right Cessation
-
2010
- 2010-09-14 IL IL208136A patent/IL208136A0/en unknown
- 2010-09-20 ZA ZA2010/06719A patent/ZA201006719B/en unknown
- 2010-09-21 CR CR11684A patent/CR11684A/es not_active Application Discontinuation
- 2010-09-21 SV SV2010003674A patent/SV2010003674A/es not_active Application Discontinuation
- 2010-09-21 EC EC2010010494A patent/ECSP10010494A/es unknown
- 2010-09-22 CO CO10117239A patent/CO6300844A2/es active IP Right Grant
- 2010-09-22 HN HN2010001920A patent/HN2010001920A/es unknown
- 2010-09-22 DO DO2010000282A patent/DOP2010000282A/es unknown
- 2010-10-20 MA MA33277A patent/MA32251B1/fr unknown
-
2011
- 2011-10-04 HK HK11110487.6A patent/HK1156306A1/xx not_active IP Right Cessation
- 2011-10-12 US US13/271,957 patent/US8580778B2/en active Active
-
2013
- 2013-10-07 US US14/047,652 patent/US20140038938A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20091732A1 (es) | Dihidropirazolonas sustituidas y su uso | |
CY1113084T1 (el) | ΠΑΡΑΓΩΓΟ ΒΕΝΖΙΜΙΔΑΖΟΛΗΣ ΚΑΙ Η ΧΡΗΣΗ ΑΥΤΟΥ ΩΣ ΑΝΤΑΓΩΝΙΣΤΟΥ ΤΟΥ ΥΠΟΔΟΧΕΑ aii | |
CY1118658T1 (el) | Συνθεση 18f-ραδιοεπισημασμενων στυρυλοπυριδινων απο τοσυλικες προδρομες ενωσεις και σταθερες φαρμακευτικες συνθεσεις αυτων | |
PE20080951A1 (es) | DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS | |
CY1115944T1 (el) | Παραγωγα 4-(ινδολ-7-υλοκαρβονυλαμινομεθυλο)κυκλοεξανοκαρβοξυλικου οξεος ως ανταγωνιστες του ερ4 υποδοχεα χρησιμοι για την αντιμετωπιση χρονιας νεφρικης ανεπαρκειας ή διαβητικης νεφροπαθειας | |
ATE429427T1 (de) | Pyrimidinderivate als orexin-rezeptorantagonisten | |
DK2358717T3 (da) | Aminotetrahydropyraner som dipeptidylpeptidase-iv-inhibitorer tilbehandling eller forebyggelse af diabetes | |
PE20110298A1 (es) | Derivados de picolinamida como inhibidores de cinasa | |
PE20161066A1 (es) | Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos | |
PE20070808A1 (es) | COMPUESTOS DERIVADOS DE ISOQUINOLINA COMO INHIBIDORES DE Rho-QUINASA | |
PE20121088A1 (es) | Nuevos compuestos eficaces como inhibidores de la xantina-oxidasa, metodo para la preparacion de los mismos y composicion farmaceutica que los contiene | |
PE20090816A1 (es) | Derivados de pirrolopirimidinona como agentes ligandos de los receptores p2x3 | |
GT200600134A (es) | Compuestos novedosos de derivados de aminosulfonilo | |
BR122013025375B8 (pt) | compostos orgânicos, seus métodos de preparo e uso, bem como composições farmacêuticas | |
PE20090649A1 (es) | DERIVADOS DE PIRAZOL COMO INHIBIDORES DE LA ENZIMA 11ßHSD1 | |
PE20120058A1 (es) | Derivados de imidazopirazina como inhibidores de syk | |
PE20060937A1 (es) | Derivados de sulfonilbencimidazol como agonistas del receptor cannabinoide 2 (cb2) | |
CY1110108T1 (el) | Παραγωγα ισοκινολινης ως αναστολεις της rho-κινασης | |
PE20140244A1 (es) | Composicion farmaceutica, metodos de tratamiento y usos de la misma | |
PE20100138A1 (es) | Derivados de morfolino pirimidina usados en enfermedades relacionadas en mtor quinasa y/o pi3k | |
EA201070912A1 (ru) | Производные оксима в качестве ингибиторов hsp90 | |
AR059249A1 (es) | Compuesto amina trisustituido | |
CL2009000394A1 (es) | Compuestos derivados de n-(1h-indazol-5-il)pirrolidin-3-carboxamida sustituida, inhibidores de erk; composicion farmaceutica; y su uso en el tratamiento del cancer. | |
PE20120635A1 (es) | Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas | |
PE20161405A1 (es) | Analogos de cortistatina y sintesis y usos de los mismos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration | ||
AE | Restoration of lapsed or forfeited application | ||
FG | Grant, registration | ||
FD | Application declared void or lapsed |